| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/08/2004 | US20040005325 Helicobacter felis vaccine |
| 01/08/2004 | US20040005324 Identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies |
| 01/08/2004 | US20040005323 Efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human |
| 01/08/2004 | US20040005322 Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| 01/08/2004 | US20040005320 Treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Adult |
| 01/08/2004 | US20040005319 Connective tissue growth factor |
| 01/08/2004 | US20040005318 Method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. |
| 01/08/2004 | US20040005317 Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells |
| 01/08/2004 | US20040005316 Use of HMG fragments as anti-inflammatory agents |
| 01/08/2004 | US20040005315 Administering an immunosuppressive agent that depletes T cells and anti-alpha beta T cell receptor antibodies, and implanting an allograft into the recipient. |
| 01/08/2004 | US20040005314 Apo-2l receptor agonist and cpt-11 synergism |
| 01/08/2004 | US20040005313 Use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/08/2004 | US20040005311 Including a core of lysine and bromelain and, optionally, including lycopene; can be used to alleviate dementia-related symptoms. |
| 01/08/2004 | US20040005310 In a receptacle in which the gas pressure is between 1 mbar and atmospheric pressure; especially for a blood coagulation factor, the von Willebrand factor or albumin. |
| 01/08/2004 | US20040005309 Targeted therapeutic proteins |
| 01/08/2004 | US20040005308 Composition and method for treating non-bacterial prostatitis |
| 01/08/2004 | US20040005307 Modulators of amyloid aggregation |
| 01/08/2004 | US20040005306 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 01/08/2004 | US20040005305 Nutritional composition for treating an immune condition |
| 01/08/2004 | US20040005304 Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| 01/08/2004 | US20040005294 Insulin-like growth factor binding protein expression can be diagnostic of cancer development and progression. |
| 01/08/2004 | US20040005293 High capacity recombinant adenoviral vector for treatment of hemophilia A |
| 01/08/2004 | US20040005291 Modulating antigen specific immune responses, treating autoimmune diseases, such as multiple sclerosis, and cancer, and for modulating cell growth. |
| 01/08/2004 | US20040005276 Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis |
| 01/08/2004 | DE10327937A1 Cyclophilin D und Creatinkinase als Apoptose-Repressoren Cyclophilin D and creatine kinase as apoptosis-repressors |
| 01/08/2004 | DE10227506A1 Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Ring-substituted Diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
| 01/08/2004 | DE10227294A1 Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung Preparations for nasal administration selected, derived from amino acids CGRP-antagonists as well as methods for their preparation |
| 01/08/2004 | DE10226814A1 Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände New drug combinations for the treatment of ischemic conditions |
| 01/08/2004 | DE10224844A1 Nicht-peptidische BRS-3-Agonisten Non-peptidic BRS-3 agonist |
| 01/08/2004 | DE10163755A1 Tumor-Peptidantigene aus humanem CD19-Protein Tumor peptide antigens from human CD19 protein |
| 01/08/2004 | DE10057290B4 Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten To be administered enterally supplement for parenteral nutrition or partial enteral / oral nutrition in critically ill patients, chronically ill and malnourished |
| 01/08/2004 | CA2844639A1 Method for the treatment of multiple sclerosis |
| 01/08/2004 | CA2672551A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | CA2513143A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | CA2492057A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | CA2492053A1 Peptides with antimicrobial properties and compounds containing same, particularly for preserving food |
| 01/08/2004 | CA2491567A1 Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| 01/08/2004 | CA2491540A1 Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders |
| 01/08/2004 | CA2491344A1 Marked peptides having affinity for a phospholipid and uses |
| 01/08/2004 | CA2491343A1 Peptides having affinity for a phospholipid and uses |
| 01/08/2004 | CA2491156A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2491083A1 Novel polynucleotide and polypeptide sequences and uses thereof |
| 01/08/2004 | CA2491034A1 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | CA2491001A1 Novel use of lipopeptide preparations |
| 01/08/2004 | CA2490950A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2490885A1 Avian cytokines, such as il-12, comprising a p40 and/or p35 subunit(s) |
| 01/08/2004 | CA2490868A1 Method of up-regulating tumor antigen expression using thymalfasin |
| 01/08/2004 | CA2490804A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | CA2490713A1 Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| 01/08/2004 | CA2490621A1 Cngh0005 polypeptides, antibodies, compositions, methods and uses |
| 01/08/2004 | CA2490547A1 Disinfecting composition |
| 01/08/2004 | CA2490533A1 Cngh0004 polypeptides, antibodies, compositions, methods and uses |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490409A1 Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490367A1 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 01/08/2004 | CA2490290A1 Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins |
| 01/08/2004 | CA2490282A1 Use of casein peptides for treating hypertension |
| 01/08/2004 | CA2490261A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | CA2490256A1 Novel variants of the papm polypeptide of bacteria of genus streptomyces |
| 01/08/2004 | CA2490129A1 Compositions and methods comprising protein activated receptor antagonists |
| 01/08/2004 | CA2489942A1 Satiety inducing composition |
| 01/08/2004 | CA2489771A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | CA2489552A1 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | CA2489376A1 Methods of organ regeneration |
| 01/08/2004 | CA2487712A1 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | CA2486538A1 Pain signaling molecules |
| 01/08/2004 | CA2486531A1 Compositions and method for enhanced mucosal delivery of interferon beta |
| 01/08/2004 | CA2473733A1 Cytokine receptor zcytor17 multimers |
| 01/08/2004 | CA2472438A1 Mannose binding protein for use in anti-hiv treatment |
| 01/08/2004 | CA2392863A1 A high capacity recombinant adenoviral vector for treatment of hemophilia a |
| 01/07/2004 | EP1378810A2 System and methods to regulate use of consumer devices and services |
| 01/07/2004 | EP1378573A1 Interleukin 1 beta protease and interleukin 1 beta protease inhibitors |
| 01/07/2004 | EP1378572A1 Bmp-11 compositions |
| 01/07/2004 | EP1378571A1 5' ESTs for secreted proteins expressed in various tissues |
| 01/07/2004 | EP1378570A1 Flk-1 is a receptor for vascular endothelial growth factor |
| 01/07/2004 | EP1378525A2 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods |
| 01/07/2004 | EP1378524A2 Recombinant thrombin receptor antibodies and their use |
| 01/07/2004 | EP1378522A2 Methods of enhancing bioactivity of chemokines |
| 01/07/2004 | EP1378518A1 RGS2 as a biomarker for macrophage activation and for activated-macrophage-related disorder |
| 01/07/2004 | EP1378517A1 Phosphoinositolglycan (PIG) binding protein from adipocytes |
| 01/07/2004 | EP1378516A1 Mixture of recombinant vaccinia vectors as polyenv vaccines for HIV |
| 01/07/2004 | EP1378515A1 Peptides for inducing apoptosis in tumor cells |
| 01/07/2004 | EP1378241A1 Pharmaceutical compositions comprising arsenic for the treatment of melanoma |
| 01/07/2004 | EP1378240A2 Pharmaceutical compositions comprising arsenic for the treatment of multiple myeloma |
| 01/07/2004 | EP1377833A2 Gastrointestinal glutathione peroxidase in hepatitis c virus infections |
| 01/07/2004 | EP1377680A2 Diagnosis and treatment of cancer: i |
| 01/07/2004 | EP1377676A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 01/07/2004 | EP1377660A2 Vaccine against the nile fever virus |
| 01/07/2004 | EP1377611A2 Muteins of hypoxia inducible factor alpha and methods of use thereof |
| 01/07/2004 | EP1377610A2 Osteoprotegerin in milk |
| 01/07/2004 | EP1377609A2 Mhc molecule constructs and their uses for diagnosis and therapy |
| 01/07/2004 | EP1377607A2 Nucleic acid sequences of hyperplasies and tumors of the thyroid |
| 01/07/2004 | EP1377601A2 Type b botulism toxin inhibitors |
| 01/07/2004 | EP1377596A1 Ttk in diagnosis and as a therapeutic target in cancer |
| 01/07/2004 | EP1377595A2 Antisense modulation of histone deacetylase 1 expression |
| 01/07/2004 | EP1377542A1 Hiv protease inhibitors based on amino acid derivatives |
| 01/07/2004 | EP1377319A2 Fusion proteins |
| 01/07/2004 | EP1377313A1 Enzymes combination coadjuvating in the interferon therapy |
| 01/07/2004 | EP1377312A1 Anthrax lethal factor inhibits tumor growth and angiogenesis |
| 01/07/2004 | EP1377311A2 Treatment of neuropathologies associated with expression of tnf-alpha |